Fig. 6. Effect of rhHAPLN1 on cell proliferation in HUVECs. (A) Cell cycle progression was assessed by flow cytometric analysis. The percentage of cells in cell cycle G1 and S/G2 phases was quantified in young HUVECs treated with IL-17A and rhHAPLN1. (B) Cell cycle progression was assessed by flow cytometric analysis. The percentage of cells in the G1 and S/G2 phases was quantified in senescent HUVECs treated with rhHAPLN1. (C, D) The protein levels of Cyclin E and CDK2 in the various groups were determined by western blot analysis.
© Biomolecules & Therapeutics
